Federal Register of Legislation - Australian Government

Primary content

PB 96 of 2020 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine originator brands of pharmaceutical items for four drugs moving to the F2 formulary on 1 October 2020, in addition to changing the brand name of one existing Pharmaceutical Benefits Scheme listed pharmaceutical item on the F2 formulary as requested by the sponsor company.
Administered by: Health
Registered 30 Sep 2020
Tabling HistoryDate
Tabled HR06-Oct-2020
Tabled Senate06-Oct-2020
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 96 of 2020

 

National Health (Originator Brand) Amendment Determination 2020 (No. 6)

 I, Thea Connolly, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination.

Dated 28 September 2020                  

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

 

 

 

 

 

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           1

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)                            1

 

 


1  Name

                   This instrument is the National Health (Originator Brand) Amendment Determination 2020 (No. 6).

                   This instrument may also be cited as PB 96 of 2020.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

 1 October 2020

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 99ADB(6B) of the National Health Act 1953

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1  Schedule 1, (after table item 96A)

Insert:

96B

Gefitinib

Iressa

 

 

2  Schedule 1, (after table item 106A)

Insert:

106B

Hydroxycarbamide

Hydrea

 

 

3  Schedule 1, (after table item 109A)

Insert:

109B

Icatibant

Firazyr

 

 

4  Schedule 1, (table item 156)

Repeal the items:

156

Morphine

DBL Morphine Pentahydrate

Injection

 

 

 

MS Contin

MS Contin Suspension 100 mg

MS Contin Suspension 20 mg

MS Contin Suspension 200 mg

MS Contin Suspension 30 mg

MS Contin Suspension 60 mg

 

 

 

Substitute:

156

Morphine

DBL Morphine Sulfate Pentahydrate

Injection

 

 

 

MS Contin

MS Contin Suspension 100 mg

MS Contin Suspension 20 mg

MS Contin Suspension 200 mg

MS Contin Suspension 30 mg

MS Contin Suspension 60 mg

 

 

5  Schedule 1, (after table item 218)

Insert:

218A

Tadalafil

Adcirca